presentación de powerpoint - eu-lac...

EU-LAC HEALTH has received funding from the European Union`s Seventh Framework

Programme (FP7/2007-2013) under grant agreement n° 281459.

Horizon2020 SC1 – Health, Demographic change and Wellbeing – Opportunities in Health (2016-2017)”

1

Caterina Buonocore NCP SC1 “Health, Demographic change and Wellbeing”

APRE - Italy



AGENDA

Context H2020

Opportunities in Health

Next Work Programme 2018-2020

2



Health Research & Innovation in H2020



Health Research in H2020



Excellent Science

European Research Council

Frontier research by the best individual teams

Future and Emerging Technologies

Collaborative research to open new fields of innovation

Marie Skłodowska Curie actions

Opportunities for training and career development

Research infrastructures (including e-infrastructure)

Ensuring access to world-class facilities

Industrial Technologies

Leadership in enabling and industrial technologies

ICT, nanotechnologies, materials, biotechnology, manufacturing, space

Access to risk finance

Leveraging private finance and venture capital for research and innovation

Innovation in SMEs

Fostering all forms of innovation in all types of SMEs

Societal Challenges

Health, demographic change and wellbeing

Food security, sustainable agriculture, marine and maritime research & the bioeconomy

Secure, clean and efficient energy

Smart, green and integrated transport

Climate action, resource efficiency and raw materials

Inclusive, innovative and reflective societies

Secure societies

European Institute of Innovation and Technology (EIT)

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)

Structure of Horizon 2020

5

HEALTH

INDIVIDUAL RESEARCHER doing High risk/frontier Research

ERC

INDIVIDUAL RESEARCHER targeting dev. of research career and training

MSCA

GROUP of researchers/actors doing basic/visionary but feasible research on technological aspects FET

GROUP of researchers/actors doing research on

Key enabling Technologies

NMP-b

ICT

Materials

ONE or more SME developing

solutions close to market

GROUP of Researchers/actors doing collaborative

multidisciplinary research

SME Instrument

SC1, 2, 3, 7..

STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?



References in current WP 2016-17

Sentence in Introduction "Health challenges are global (…) include the international dimension…"

Reference to international dimension and/or to specific multi-lateral initiatives:

• SC1-PM-01; SC1-PM-03; SC1-PM-06; SC1-PM-08; SC1- PM-14; SC1-HCO-04; SC1-HCO-07; SC1-HCO-14

Some topics refer to specif countries



SC1 and international cooperation

Reference to specific multi-lateral initiatives

Mutual opening of research programmes with Third Countries (USA)

Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (Switzerland, Australia)

Specific actions

SC1. HEALTH,

DEMOGRAPHIC

CHANGE

AND

WELLBEING

9



Less prescriptive topic texts

Two-year work programme

Stronger focus on end users

Broad topics

Pers. Medicine

Clinical trials

Work Programme SC1 2016-2017



Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using

molecular profiling for tailoring the right therapeutic

strategy for the right person at the right time, and/or

to determine the predisposition to disease and/or to deliver

timely and targeted prevention"



SC1 Work Programme 2017 in brief

SME Instrument 2 topics (unchanged from 2016)

Other Actions 12 items (incl. InnovFin ID and Birth

Day Prize)

Including 'Coordination activities' 4 topics

Call 'Personalised Medicine' 11 topics



Health in H2020

Health solutions can imply different phases of research and innovation

13 INNOVATION

RESEARCH



Call Budget Deadline

SC1-PM-03–2017 New concepts in patient stratification

€15M 11 Apr.2017

SC1-PM-11–2017: Clinical research on regenerative medicine

€30M 11 Apr. 2017

SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age

€25M 31 Jan. 2017

SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products

€19M 14 Mar. 2017

SC1-PM-17 – 2017: Personalised computer models and in-silico systems for well-being

€19M 14 Mar. 2017

SC1-PM-19–2017: PPI for uptake of standards for the exchange of digitalised healthcare records

€8.26M 14 Mar. 2017

SC1-PM-20-2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector

€9M 11 Apr. 2017

SC1 topics – 2017



SC1 topics – 2017 – Other actions

SC1 Work Programme (updated at 25 July 2016) http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016_2017/main/h2020-wp1617-health_en.pdf

Mostra Desktop.scf

Call Budget Deadline

SC1-HCO-08–2017:

Actions to bridge the divide in European health research and

innovation

€1M 11 Apr. 2017

SMEInst-05-2016-2017: (for EU SME’s)

Supporting innovative SMEs in the healthcare biotechnology

sector:

a. Cell technologies in medical applications

b. Clinical research for the validation of biomarkers and/or

diagnostic medical devices*

SMEInst-06-2016-2017:

SMEInst-06-2016-2017 - Accelerating market introduction of ICT

solutions for Health, Well-Being and Ageing Well

€53M (2016)

€57.3M (2017)

Multiple cut-off

dates in 2016 and

2017

InnovFin Infectious Diseases (InnovFin ID) Pilot €50M (2016)

€50M (2017)

From first quarter

of 2016

Inducement prize on reducing maternal and new-born

morbidity and mortality - Birth Day Prize €1M 2017



• Adoption planned for 4th quarter 2017 • Strategic Programme - Draft Scoping Paper for SC1:

Next SC1 Work Programme 2018-2020

• Priority 1: Better health and care, economic growth and sustainable health systems

a. Personalized medicine

b. Innovative health and care industry

c. Improving global health

d. Sustainable and evidence-based health and care systems

e. Innovative health and care delivery services – Integration of care

• Priority 2: Decoding the role of the overall environment for health and well-being

a. The human exposome

b. Global changes and health (possible contribution to focus area COP21)

• Priority 3: Digital transformation in Health and Care

a. eHealth and mHealth

b. ICT for Active and Healthy Ageing

• Priority 4: Trusted Big Data solutions and Cybersecurity for Health and Care

a. Trusted Big Data solutions for health and care

b. Cybersecurity for health and care



Open to the world Multi-lateral health research activities

www.irdirc.org http://intbir.nih.gov/

http://ihec-epigenomes.org/

https://icgc.org/

G2MC

www.gacd.org/

http://www.glopid-r.org/

http://www.irdirc.org/

http://intbir.nih.gov/




http://www.iom.edu/Activities/Research/GenomicBasedResearch/Innovation-Collaboratives/Global_Genomic_Medicine_Collaborative.aspx




http://www.gacd.org/






Global Alliance for Chronic diseases (GACD): Mexico, Argentina e Brazil, Cuba (tbc)

Global Research Collaboration for Infectious Disease Preparedness (GloPID-R): Mexico, Argentina e Brazil, Cuba (tbc)

Joint Programmining Initiative on Anti-Microbial Resistance (JPIAMR): Argentina

Participation of LAC



Participation of LAC in Zika call

SC1-PM-22-2016: Addressing the urgent research gaps against the Zika virus and other emerging threats in Latin America

Country Participation

Participation in Retained Proposals

Argentina 1 1 Bolivia 1 0 Brazil 50 14

Colombia 6 3 Cuba 3 2

Dominican Republic 1 0 Ecuador 1 1

Guatemala 1 0 Mexico 3 2

Peru 1 0 Venezuela 1 0

3 projects funded: ZikaPLAN ZIKAction ZikAlliance

More info: https://ec.europa.eu/research/health/index.cfm?pg=area&areaname=zika



More info @

Horizon 2020 (general + funding) http://ec.europa.eu/research/participants/portal/desktop/en/home.html

International cooperation website http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-

cutting-issues/international-cooperation_en.htm

Funding of Third countries http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cp art/h2020-hi-

3cpart_en.pdf

Associated countries

http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cpart/h2020-hi-list-ac_en.pdf



Thanks for your attention!

APRE Agenzia per la Promozione della Ricerca Europea

via Cavour, 71 00184 - Roma

www.apre.it Tel. (+39) 06-48939993

Fax. (+39) 06-48902550

Caterina Buonocore

Health NCP [email protected]

http://www.apre.it/

presentación de powerpoint - eu-lac...

Documents